SCHEMBL9905948

SCHEMBL9905948

CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCC(=O)OCC(O)CO

nearest known ligand 0.68

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FAAH O00519 4/20 0.68
DGKA P23743 1/20 0.59
ADORA3 P0DMS8 2/20 0.53
KMT2A Q03164 2/20 0.53
KDM4E B2RXH2 1/20 0.53
DUSP3 P51452 1/20 0.53
NR1I2 O75469 1/20 0.53
PGR P06401 1/20 0.53
PTGS2 P35354 1/20 0.53
PDE4D Q08499 1/20 0.53
MEN1 O00255 1/20 0.53
LMNA P02545 1/20 0.53
ALDH1A1 P00352 5/20 0.50
CYP3A4 P08684 1/20 0.50
ALOX15 P16050 1/20 0.50
TSHR P16473 1/20 0.50
HSD17B10 Q99714 1/20 0.50
TDP1 Q9NUW8 1/20 0.50
CYP19A1 P11511 2/20 0.49
RXRA P19793 2/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28163384 0.95 DGKA (0.64) FAAHDGKAADORA3KMT2AKDM4E
SCHEMBL15451530 0.91 FAAH (0.82) FAAHDGKAADORA3KMT2AKDM4E
SCHEMBL9905949 0.91 FAAH (0.82) FAAHDGKAADORA3KMT2AKDM4E
SCHEMBL29376090 0.90 FAAH (0.80) FAAHDGKAADORA3KMT2AKDM4E
SCHEMBL10037042 0.89 FAAH (0.55) FAAHDGKAADORA3KMT2ANR1I2
1-Monolinolenin SCHEMBL23611225 0.89 FAAH (0.78) FAAHDGKAADORA3KMT2AKDM4E
SCHEMBL9905950 0.89 FAAH (0.78) FAAHDGKAADORA3KMT2AKDM4E
SCHEMBL13623309 0.89 FAAH (0.78) FAAHDGKAADORA3KMT2AKDM4E
1-Monolinolenin SCHEMBL1580284 0.89 FAAH (0.78) FAAHDGKAADORA3KMT2AKDM4E
1-Monolinolenin SCHEMBL23611226 0.89 FAAH (0.78) FAAHDGKAADORA3KMT2AKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230355564-A1 CANNABINOIDS COMPOSITIONS WITH POLYUNSATURATED FATTY ACID MONOGLYCERIDES, METHODS AND USES THEREOF SCF PHARMA INC. (CA) 2023-11-09 US disclosed
US-11701337-B2 Polyunsaturated fatty acid monoglycerides, compositions, methods and uses thereof SCF PHARMA INC. (CA) 2023-07-18 US disclosed
US-9925165-B2 Compositions comprising polyunsaturated fatty acid monoglycerides or derivatives thereof and uses thereof SCF PHARMA INC. (CA) 2018-03-27 US disclosed
US-9925165-B2 Compositions comprising polyunsaturated fatty acid monoglycerides or derivatives thereof and uses thereof SCF PHARMA INC. (CA) 2018-03-27 US disclosed
US-20170014369-A1 COMPOSITIONS COMPRISING POLYUNSATURATED FATTY ACID MONOGLYCERIDES OR DERIVATIVES THEREOF AND USES THEREOF SCF PHARMA INC. (CA) 2017-01-19 US disclosed
US-20170014369-A1 COMPOSITIONS COMPRISING POLYUNSATURATED FATTY ACID MONOGLYCERIDES OR DERIVATIVES THEREOF AND USES THEREOF SCF PHARMA INC. (CA) 2017-01-19 US disclosed
US-9480660-B2 Methods for treating inflammatory diseases with compositions comprising polyunsaturated fatty acid monoglycerides or derivatives thereof SCF PHARMA INC. (CA) 2016-11-01 US disclosed
US-9480660-B2 Methods for treating inflammatory diseases with compositions comprising polyunsaturated fatty acid monoglycerides or derivatives thereof SCF PHARMA INC. (CA) 2016-11-01 US disclosed
US-9233915-B2 Polyunsaturated fatty acid monoglycerides, derivatives, and uses thereof SCF PHARMA INC. (CA) 2016-01-12 US disclosed
US-9233915-B2 Polyunsaturated fatty acid monoglycerides, derivatives, and uses thereof SCF PHARMA INC. (CA) 2016-01-12 US disclosed
US-20100196496-A1 COMPOSITIONS COMPRISING POLYUNSATURATED FATTY ACID MONOGLYCERIDES OR DERIVATIVES THEREOF AND USES THEREOF SCF PHARMA INC. (CA) 2010-08-05 US disclosed
US-20100196496-A1 COMPOSITIONS COMPRISING POLYUNSATURATED FATTY ACID MONOGLYCERIDES OR DERIVATIVES THEREOF AND USES THEREOF SCF PHARMA INC. (CA) 2010-08-05 US disclosed
US-20100160261-A1 POLYUNSATURATED FATTY ACID MONOGLYCERIDES, DERIVATIVES, AND USES THEREOF SCF PHARMA INC. (CA) 2010-06-24 US disclosed
US-20100160261-A1 POLYUNSATURATED FATTY ACID MONOGLYCERIDES, DERIVATIVES, AND USES THEREOF SCF PHARMA INC. (CA) 2010-06-24 US disclosed
US-20090292019-A1 POLYUNSATURATED FATTY ACID MONOGLYCERIDES, DERIVATIVES, AND USES THEREOF SCF PHARMA INC. (CA) 2009-11-26 US disclosed
US-20090291102-A1 COMPOSITIONS COMPRISING POLYUNSATURATED FATTY ACID MONOGLYCERIDES OR DERIVATIVES THEREOF AND USES THEREOF SCF PHARMA INC. (CA) 2009-11-26 US disclosed
US-20090292019-A1 POLYUNSATURATED FATTY ACID MONOGLYCERIDES, DERIVATIVES, AND USES THEREOF SCF PHARMA INC. (CA) 2009-11-26 US disclosed
US-20090291102-A1 COMPOSITIONS COMPRISING POLYUNSATURATED FATTY ACID MONOGLYCERIDES OR DERIVATIVES THEREOF AND USES THEREOF SCF PHARMA INC. (CA) 2009-11-26 US disclosed
WO-2008113177-A1 COMPOSITIONS COMPRISING POLYUNSATURATED FATTY ACID MONOGLYCERIDES OR DERIVATIVES THEREOF AND USES THEREOF CENTRE DE RECHERCHE SUR LES BIOTECHNOLOGIES MARINES (CA) 2008-09-25 WO disclosed
WO-2008098375-A1 POLYUNSATURATED FATTY ACID MONOGLYCERIDES, DERIVATIVES, AND USES THEREOF CENTRE DE RECHERCHE SUR LES BIOTECHNOLOGIES MARINES (CA) 2008-08-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230355564-A1 CANNABINOIDS COMPOSITIONS WITH POLYUNSATURATED FATTY ACID MONOGLYCERIDES, METHODS AND USES THEREOF CNR2, SGMS2, SGMS1 FAAH 4/4885DGKA 33/4885ADORA3 668/4885
US-20100196496-A1 COMPOSITIONS COMPRISING POLYUNSATURATED FATTY ACID MONOGLYCERIDES OR DERIVATIVES THEREOF AND USES THEREOF MGLL, PNLIP, FASN FAAH 871/4885DGKA 40/4885ADORA3 1612/4885
US-20090292019-A1 POLYUNSATURATED FATTY ACID MONOGLYCERIDES, DERIVATIVES, AND USES THEREOF FASN, MGLL, FADS1 FAAH 225/4885DGKA 36/4885ADORA3 2402/4885
US-20170014369-A1 COMPOSITIONS COMPRISING POLYUNSATURATED FATTY ACID MONOGLYCERIDES OR DERIVATIVES THEREOF AND USES THEREOF PPARG, PTGES, PTGIS FAAH 267/4885DGKA 102/4885ADORA3 1724/4885
US-11701337-B2 Polyunsaturated fatty acid monoglycerides, compositions, methods and uses thereof CPT2, AGK, GSR FAAH 120/4885DGKA 130/4885ADORA3 1466/4885
US-20090291102-A1 COMPOSITIONS COMPRISING POLYUNSATURATED FATTY ACID MONOGLYCERIDES OR DERIVATIVES THEREOF AND USES THEREOF MGLL, PNLIP, FASN FAAH 871/4885DGKA 40/4885ADORA3 1612/4885
US-20100160261-A1 POLYUNSATURATED FATTY ACID MONOGLYCERIDES, DERIVATIVES, AND USES THEREOF FASN, MGLL, FADS1 FAAH 225/4885DGKA 36/4885ADORA3 2402/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.